2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)carboxamide: A potent inhibitor of NF-κB- and AP- 1-mediated gene expression identified using solution-phase combinatorial chemistry

Journal of Medicinal Chemistry

Volumn 41, Issue 4, 1998, Pages 413-419

  Sullivan, Robert W ^a   Bigam, Colin G ^a   Erdman, Paul E ^a   Palanki, Moorthy S S ^a   Anderson, David W ^a   Goldman, Mark E ^a   Ransone, Lynn J ^a   Suto, Mark J ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 (TRIFLUOROMETHYL)PYRIMIDINE 5 N [3',5' BIS(TRIFLUOROMETHYL)PHENYL]CARBOXAMIDE; AMIDE; BETA ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 8; LUCIFERASE; PHORBOL 13 ACETATE 12 MYRISTATE; PHYTOHEMAGGLUTININ; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMISTRY; DRUG POTENCY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA CELL LINE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ACTINS; ANIMALS; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; INTERLEUKIN-2; INTERLEUKIN-8; JURKAT CELLS; LUCIFERASES; MOLECULAR STRUCTURE; NF-KAPPA B; PYRIMIDINES; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TRANSFECTION;

EID: 0032510166     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970671g     Document Type: Article

References (19)

1. Manning, A. M.; Lewis, A. J. Transcription Factors, Rheumatoid Arthritis and the Search for Improved Antirheumatic Agents. Rheumatoid Arthritis 1997, 1, 65.
2. Hill, C. S.; Treisman, R. Transcriptional Regulation by Extra-cellular Signals; Mechanisms and Specificity. Cell 1995, 80, 199 and references therein.
3. Karin, M. Signal Transduction from the cell surface to the nucleus through phosphorylation of transcription factors. Curr. Biol. 1994, 6, 415.
4. Manning, A. M. Transcription factors: A new frontier for drug discovery. Drug Discovery Today 1996, 1, 151.
5. Vossen, A. C. T. M.; Savelkoul, H. F. Cytokines in clinical and experimental transplantation. J. Mediat. Inflamm. 1994, 3, 403.
6. Bauerle, P. A.; Henkel, T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 1995, 12, 141.
7. Manning, A. M.; Mercurio, F. Transcriptional Inhibitors in Inflammation. Expert Opin. Invest. Drugs 1997, 6, 555-567.
8. Lewis, A. J. Transcription Factors: New Targets for Drug Discovery. In Emerging Drugs: The prospect for Improved Medicines; Ashley Publications Ltd.: London, 1996; p 31.
9. Goldman, M. E.; Walton, T. D.; Ransone, L. J.; Suto, C. M. An integrated laboratory automation system for quantitative high throughput screening (QHTS) with cell-based assays. ISLAR '95 Proc. 1995, 27, 125.
10. Goldman, M. E.; Ransone, L. J.; Anderson, D. W.; Gaarde, W. A.; Suto, M. J.; Sullivan, R. W.; Shorthouse, R.; Morikawa, M.; Morris, R. E, SP100030 Is a Novel T-Cell-Specific Transcription Factor Inhibitor That Possesses Immunosuppressive Activity In Vivo. Transplant. Proc. 1996, 28(6), 3106.
11. Compound 1 was run in an adjuvanct arthritis model and was found to be active at 25-30 mg/mg ip. Unpublished data, Signal Pharmaceuticals.
12. Abraham, R. J.; Bedford, G. R.; Wright, B. The NMR spectra of the porphyrins. 17. Metalloporphyrins as diamagnetic shift reagents: Structural and specificity studies. Org. Magn. Reson. 1982, 18(1), 45.
13. Gayo, L. M.; Suto, M. J. Ion-Exchange Resins for Solution Phase Parallel Synthesis of Chemical Libraries. Tetrahedron Lett. 1997, 33(4), 513.
14. Biosource International, 820 Flynn Road, Camarillo, CA 93012.
15. A manuscript describing the detailed evaluation of additional 2- and/or 4-position derivatives is in preparation.
16. Compounds prepared individually and in the library were equiopotent.
17. Tritium-labeled 28 was prepared and cell uptake monitored in Jurkat T-cells, monocytes, and THP-1 cells. Tritiated 28 was shown to equally penetrate all cell types tested,
18. Unpublished results, Signal Pharmaceuticals.
19. Chanda, V. B. Current protocols in Molecular Biology; J. Wiley and Sons: New York, 1994. JM970671G